Match Document Document Title
7482006 Recombinant enterovirus 71 neutralizing antibodies and applications thereof  
Provided is an antibody against enterovirus 71 comprising the amino acid sequence shown in SEQ ID NOS: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 or functionally active homologues...
7473421 Humanized anti-CCR2 antibodies and methods of use therefor  
The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks...
7470775 Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins  
CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the...
7465785 Polypeptide encoded by a nucleic acid over-expressed in melanoma  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7446191 DNA construct encoding CE7-specific chimeric T cell receptor  
Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular...
7442550 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein  
A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the...
7439025 Antibodies binding a gamma carboxyglutamic acid displaying epitope  
Antibodies are described, which are suitable for identification of γ-carboxyglutamic acid (Gla), said antibodies having an ability of identifying Gla residues in proteins and/or peptides, while...
7435797 Anti-HER2 antibody variants  
The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains
7432352 Hybrid molecules having Factor VII/VIIa activity  
The present invention relates to novel human coagulation Factor VII/VIIa proteins having coagulant potential/activity as well as pharmaceutical compositions comprising the proteins, uses thereof,...
7432359 Anti-A33 antibody  
The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the...
7429645 Humanized anti-lymphotoxin beta receptor antibodies  
This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic...
7429644 Humanized anti-LT-β-R antibodies  
Humanized antibodies to LT-β-R and methods of use thereof are provided.
7427495 Methods of using Bcl-2 for the therapeutic treatment and prevention of diseases  
The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the...
7419659 Expression control using variable intergenic sequences  
The present invention relates to a method of production of antibodies wherein the heavy and light chains of a particular antibody molecule are encoded by the DNA present in a dicistronic message in...
7402410 Humanized immunoglobulin reactive with α4β7 integrin  
The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin...
7387873 Human myeloma cell line  
There is provided a human myeloma cell tine for use in a method for producing a human monoclonal antibody.
7381798 Recombinant antibody recognizing dioxin and gene encoding the antibody  
The present invention relates to a novel recombinant antibody having a binding activity to 2,3,4,7,8-pentachlorodibenzofuran (2,3,4,7,8-PeCDF), a gene encoding its amino acid sequence, a vector...
7381560 Expression and use of anti-CD20 antibodies  
Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of...
7361341 Methods of treating cancer using antibodies that immunospecifically bind to trail receptors  
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other...
7354999 PRO1481 polypeptides  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7342110 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same  
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced...
7339033 PRO1481  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7335634 Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers  
Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers prevents a bleeding diathesis and reduces pre-, peri- and postoperative blood loss in...
7335748 RG1 antibodies and uses thereof  
The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and...
7332582 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency  
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation...
7323311 Methods of obtaining a specific binding member that binds eotaxin  
Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The...
7321026 Framework-patched immunoglobulins  
Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described...
7319139 TAG-72 specific CH2 domain deleted antibodies  
Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may...
7314615 IκB Kinase-β (IKKβ) binding antibodies and methods of using same  
The present invention provides an isolated nucleic acid molecules encoding IκB kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that...
7306907 Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors  
The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying...
7291721 Anti-IL-6 antibodies, compositions, methods and uses  
The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at...
7291479 Method for detecting the von Willebrand factor-cleaving protease activity of ADAMTS-13  
The invention relates to a diagnostic method for determining the von Willebrand factor (VWF) cleaving activity of ADAMTS-13 in a test medium during which the test medium is mixed with 0.5 to 5 U/ml...
7285379 Artificial oxygen carrier and production method thereof  
The present invention provides a method of producing a complex of albumin and a deoxy form metal complex having a porphyrin structure, which includes mixing albumin and a metal complex having a...
7282199 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor  
Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of...
7279560 Antibody fragments to JTT-1 protein and cells secreting such antibody fragments  
Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have...
7273727 Fusion proteins for prodrug activation  
The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity...
7271145 Methods and compositions for oxygen transport comprising modified hemoglobin in plasma  
The present invention relates to blood products, and more particularly to compositions comprising a modified hemoglobin in plasma.
7261890 Methods for using canine immunoglobulin variable domains and caninized antibodies  
The present invention provides canine heavy chain and light chain (both λ and κ) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised...
7258998 Cell culture medium  
A method for culturing cells in the presence of an alcanoic acid for enhancing protein production.
7256273 Humanized antibodies that recognize beta amyloid peptide  
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
7253263 Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3  
The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and...
7250503 Nucleic acid molecules encoding clot-specific streptokinase fusion proteins possessing altered plasminogen activation characteristics  
The present invention provides polynucleotides encoding clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of...
7250494 Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria  
The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and...
7247453 Calcium binding recombinant antibody against protein C  
A Ca 2+ dependent recombinant antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C has been constructed. The...
7244592 Ligand screening and discovery  
Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second...
7238785 RS7 antibodies  
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more...
7227002 Human antibodies that bind human 17-A1/EpCAM tumor antigen  
The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens,...
7223561 Process of high purity albumin production  
A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers...
7217798 Alteration of Fc-fusion protein serum half-lives by mutagenesis  
The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250,...
7214514 Identification of human cell lines for the production of human proteins by endogenous gene activation  
A process for selecting human cells for the production of human proteins by endogenous gene activation allows human proteins to be produced in economically feasible quantities and in a form...